Fetal Cellular Immunity in Hemolytic Disease During Rh Immunization in the Second Trimester of Pregnancy
Keywords:
Rh-immunization, hemolytic disease of the fetus, T-lymphocytes CD3+, CD4+, CD8+Abstract
Purpose: The article presents the results of a study of cellular immunity indices in 20 fetuses with hemolytic disease in the second trimester of pregnancy. Materials and methods: studies were conducted on 20 umbilical cord blood of fetuses with hemolytic disease, which were taken by transabdominal cordocentesis from pregnant women with Rh-immunization from 24 to 28 weeks of gestation at the Republican Perinatal Center in 2024. All immunological studies were carried out at the Institute of Immunology of the Academy of Sciences of the Republic of Uzbekistan.
Results: the number of CD3+ T-lymphocytes, CD4+ T-helper cells and CD20+ B-lymphocytes in fetuses with hemolytic disease was significantly reduced by 2.23, 2.3 and 2 times compared to the control group; the number of CD8+ lymphocytes of cytotoxic cells and CD16+ killer lymphocytes were significantly increased by 1.3 times and 3.6 times compared to the control group;
Conclusion: In hemolytic disease, the synthesis of T-lymphocytes by the fetus increases, primarily due to the general pool of CD3+, CD4+ T-helper cells and CD20+ B-lymphocytes, which naturally contributes to an increase in CD8+ cytotoxic cells and CD16+ T -killer cells, which are the result of the fetal immunological response.
References
Prevention of Rh D alloimmunization No. 181. American College of Obstetricians and Gynecologists. Obstet Gynecol, 130 (2) (2017), pp. e57-e70, 10.1097/AOG.0000000000002232
The fetus at risk for anemia–diagnosis and management Clinical Guideline #8. Society for Maternal-Fetal Medicine. Am J Obstet Gynecol, 212 (6) (2015), pp. 697-710, 10.1016/j.ajog.2015.01.059
Management of alloimmunization during pregnancy No. 192. American College of Obstetricians and Gynecologists. Obstet Gynecol, 131 (3) (2018), pp. e82-e90, 10.1097/AOG.0000000000002528
I Moinuddin, C Fletcher, P. Millward Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women—A study from a tertiary care hospital in Southeast Michigan, J Blood Med, 10 (2019), pp. 283-289, 10.2147/JBM.S214118
NL. Van Buren, Perinatal transfusion medicine. BH Shaz, CD Hillyer, MR Gil (Eds.), Transfusion medicine and hemostasis, Elsevier Inc. (2019), pp. 301-312
Жабборов У.У., Расуль-Заде Ю.Г, Исмаилова А.А. «Цитокиновый статус плода при гемолитической болезни с резус-иммунизации матери» Инфекция, иммунитет, фармакология, Ташкент, 2020, №4. Стр.65-69.
L.C. Nwogu, K.J. Jr. Moise, K.L. Klein, H. Tint, B. Castillo, Y. Bai. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. Transfusion, 58 (2018), pp. 677-684
B.L. Houston, R. Govia, A.M. Abou-Setta, G.J. Reid, M. Hadfield, C. Menard, et al. Severe Rh alloimmunization and hemolytic disease of the fetus managed with plasmapheresis, intravenous immunoglobulin and intrauterine transfusion: a case report. Transfus Apher Sci, 53 (2015), pp. 399-402
B. Mayer, L. Hinkson, W. Hillebrand, W. Henrich, A. Salama. Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells. Transfus Med Hemother, 45 (2018), pp. 429-436
E. Maisonneuve, A. Dugas, S. Friszer, C. Toly-Ndour, L. Cariot, F. Dhombres, et al. Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study. J Gynecol Obstet Hum Reprod, 50 (2021), Article 102119
